SCHEMBL21850800

SCHEMBL21850800

Cc1ncn(-c2ncc(CN3CCNCC3)cn2)c1C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KCNJ1 P48048 3/20 0.51
▸ SIGMAR1 Q99720 1/20 0.41
▸ CXCR4 P61073 9/20 0.40
▸ MEN1 O00255 1/20 0.38
▸ CHRM2 P08172 1/20 0.38
▸ CHRM1 P11229 1/20 0.38
▸ ADRA2C P18825 1/20 0.38
▸ CCR2 P41597 1/20 0.38
▸ CXCL12 P48061 1/20 0.38
▸ BLM P54132 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ HRH3 Q9Y5N1 1/20 0.38
▸ TAAR1 Q96RJ0 1/20 0.37
▸ LMNA P02545 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ TSHR P16473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21850875 0.83 KCNJ1 (0.40) KCNJ1SIGMAR1CXCR4MEN1CHRM2
SCHEMBL14606249 0.77 SIGMAR1 (0.52) SIGMAR1CXCR4MEN1CHRM2CHRM1
SCHEMBL21850861 0.77 KCNJ1 (0.52) KCNJ1SIGMAR1CXCR4MEN1CHRM2
SCHEMBL21850871 0.76 KCNJ1 (0.49) KCNJ1SIGMAR1CXCR4MEN1CHRM2
SCHEMBL21850849 0.75 SIGMAR1 (0.44) SIGMAR1CXCR4MEN1CHRM2CHRM1
SCHEMBL25085613 0.71 SIGMAR1 (0.49) SIGMAR1CXCR4MEN1CHRM2CHRM1
SCHEMBL13937097 0.71 SIGMAR1 (0.52) SIGMAR1CXCR4MEN1CHRM2CHRM1
SCHEMBL19490798 0.71 SIGMAR1 (0.56) SIGMAR1CXCR4MEN1CHRM2CHRM1
SCHEMBL21850868 0.70 SIGMAR1 (0.41) SIGMAR1CXCR4MEN1CHRM2CHRM1
SCHEMBL26157099 0.70 TAAR1 (0.47) SIGMAR1CXCR4MEN1CHRM2CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200339550-A1 SUBSTITUTED NITROGEN CONTAINING COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2020-10-29 — — US disclosed
US-20200109135-A1 SUBSTITUTED NITROGEN CONTAINING COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2020-04-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200109135-A1 SUBSTITUTED NITROGEN CONTAINING COMPOUNDS NR0B1, GRK1, GRIN1 KCNJ1 562/4885SIGMAR1 64/4885CXCR4 666/4885
US-20200339550-A1 SUBSTITUTED NITROGEN CONTAINING COMPOUNDS NR0B1, GRK1, GRIN1 KCNJ1 562/4885SIGMAR1 64/4885CXCR4 666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback